ERBB2 and breast cancer: The ASCO guidelines (Table 1) [73] suggest the use of Oncotype Dx, MammaPrint, or BCI in postmenopausal or >50-year-old women with HR+/HER2- early BC, which is either node-negative or with 1–3 node metastases.